← Leaderboards
Hany Ramez Nassef
Nodexus, Inc.
$301,895
Attributed
$603,790
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $303.8K · FY2019–20$500K$375K$250K$125K$0
'19
'20
Funding mix
By agency
NIH$603,790 · 1
By mechanism
R43$603,790 · 1
Top collaborators
- Karthik Ratna Balakrishnan3 shared
Most similar at Nodexus, Inc.
Same institution · by research overlap
- Karthik Ratna Balakrishnan$301,895
Others in their field
Other Emerging Leaders on “Screening”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,487,925
- Lynn Briscoe · Leidos Biomedical Research, Inc.$121,890,535
- Yunda Huang · Fred Hutchinson Cancer Center$58,111,165
- Leonard Freedmand · Leidos Biomedical Research, Inc.$57,401,321
- John Damon Chodera · Sloan-Kettering Inst Can Research$53,758,943
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$33,980,897
Research focus
ScreeningBaseSamplingTechnologyLeadDetectionMicrofluidicsQuantitative Reverse Transcriptase PcrWalkingCessation Of LifeMonitorBiomarker IdentificationChemotherapeutic AgentBiomarker PanelBiomarker DiscoveryCancer SubtypesBiological MarkersCisplatinCell SeparationCell SurvivalCancer CellCancer Stem CellCalibrationBenchmarking
Grant awards (3)
An urgently needed low-cost, rapidly deployable platform for simultaneous SARS-CoV-2 viral particle and COVID-19 IgG/IgM detection and quantification$248,790
R43 · FY2020 · CA
A Label-Free, Many-Parameter Benchtop Platform for Functionally-Preserved, Viable Cancer Stem Cell Isolation and Biomarker Discovery to Probe Urothelial Carcinoma of the Bladder$55,000
R43 · FY2020 · CA
A Label-Free, Many-Parameter Benchtop Platform for Functionally-Preserved, Viable Cancer Stem Cell Isolation and Biomarker Discovery to Probe Urothelial Carcinoma of the Bladder$300,000
R43 · FY2019 · CA